Document is current
Any future updates will be listed below
-
Authors
Bobisse, Sara
Bianchi, Valentina
Tanyi, Janos L.
Sarivalasis, Apostolos
Missiaglia, Edoardo
Pétremand, Rémy https://orcid.org/0000-0002-7629-7336
Benedetti, Fabrizio https://orcid.org/0000-0002-9959-9142
Torigian, Drew A.
Genolet, Raphael https://orcid.org/0000-0001-9335-3945
Barras, David https://orcid.org/0000-0001-8985-4704
Michel, Alexandra
Mastroyannis, Spyridon A. https://orcid.org/0000-0003-1333-2269
Zsiros, Emese
Dangaj Laniti, Denarda
Tsourti, Zoi
Stevenson, Brian J.
Iseli, Christian https://orcid.org/0000-0002-2296-2863
Levine, Bruce L. https://orcid.org/0000-0001-6971-8465
Speiser, Daniel E. https://orcid.org/0000-0003-2031-3250
Gfeller, David https://orcid.org/0000-0002-3952-0930
Bassani-Sternberg, Michal https://orcid.org/0000-0002-1934-954X
Powell, Daniel J. Jr https://orcid.org/0000-0002-5966-8908
June, Carl H. https://orcid.org/0000-0003-0241-3557
Dafni, Urania
Kandalaft, Lana E. https://orcid.org/0000-0002-1575-6674
Harari, Alexandre https://orcid.org/0000-0002-1055-2090
Coukos, George https://orcid.org/0000-0001-8813-7367
- License Information
-
More Information
Article History
Received: 18 March 2022
Accepted: 24 July 2023
First Online: 21 September 2023
Competing interests
: G.C. has received grants and research support from or has been a coinvestigator in clinical trials for Bristol-Myers Squibb, Celgene, Boehringer Ingelheim, Roche, Tigen Pharma, Iovance and Kite. The Lausanne University Hospital (CHUV) has received honoraria for advisory services G.C. has provided to Roche, Genentech, AstraZeneca AG, Bristol-Myers Squibb SA, F. Hoffmann-La Roche AG, MSD Merck AG and Geneos Therapeutics. G.C. is a coinventor in patents in the domains of tumor-infiltrating lymphocyte (TIL) expansion, T cell engineering, antibodies and tumor vaccines. Patents related to the NeoTIL technology from the Coukos laboratory have been licensed by the Ludwig Institute, also on behalf of the University of Lausanne and the CHUV, to Tigen Pharma. G.C. has previously received royalties from the University of Pennsylvania for CAR-T cell therapy licensed to Novartis and Tmunity Therapeutics. E.Z. has received research support from Merck and Co. and honoraria for advisory services from Celldex and Iovance Biotherapeutics. C.H.J. receives royalties paid from Novartis and Kite to the University of Pennsylvania. C.H.J. is a scientific cofounder and holds equity in Capstan Therapeutics, Dispatch Biotherapeutics and Bluewhale Bio. C.H.J. serves on the board of AC Immune and is a scientific advisor to BluesphereBio, Cabaletta, Carisma, Cartography, Cellares, Cellcarta, Celldex, Danaher, Decheng, ImmuneSensor, Kite, Poseida, Verismo, Viracta and WIRB-Copernicus group. B.L.L. serves on scientific advisory boards for Akron Bio, Avectas, Immuneel, Immusoft, In8bio, Ori Biotech, Oxford Biomedica, Thermo Fisher Scientific, Pharma Services, UTC Therapeutics and Vycellix, and is a cofounder and equity holder of Tmunity Therapeutics (Kite) and Capstan Therapeutics. These relationships are managed in accordance with University of Pennsylvania policy and oversight. The remaining authors declare no competing interests.
